retatrutide clinical trial phase Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in weight and A1C Retatrutide: FDA approval time, trial

Potential Mechanisms of Hair Loss with GLP-1 Medications Several biological mechanisms might explain why GLP-1 medications could lead to hair loss

The use of basket trials within the core registration program is novel in the cardiometabolic disease space and improves the efficiency and speed with which the impact of obesity treatment on multiple complications can be understood

Because retatrutide is an unlicensed investigational medicine, participants in clinical trials should follow the specific training and instructions for use (IFU) provided by their trial team and the device manufacturer

For most patients, standard-dose semaglutide or tirzepatide is more likely to produce faster and more noticeable weight loss because the dose strategy is designed to reach stronger appetite-suppressing levels over time

Strategies for minimizing muscle loss during use of incretinmimetic drugs for treatment of obesity